Core Viewpoint - The ongoing trademark dispute between Jia Duo Bao and Wang Lao Ji has intensified, with both companies making significant claims regarding their rights to the "Wang Lao Ji" brand in international markets [4][6][14]. Group 1: Trademark Ownership Claims - Jia Duo Bao asserts that it acquired the overseas trademark rights for "Wang Lao Ji" in the early 2000s and has since registered the trademark in over 60 countries [4][9]. - Wang Lao Ji claims that the current trademark owner is Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., and that it has registered the "Wang Lao Ji" and "WALOVI" trademarks in over 100 countries [13][14]. Group 2: Recent Developments - In August 2023, Wang Lao Ji launched its international core brand "WALOVI" and introduced four international canned products [6]. - Jia Duo Bao reported victories in multiple lawsuits in Canada and the EU, defending its overseas trademark rights [9]. Group 3: Historical Context - The trademark dispute dates back to 2012 when an arbitration ruling invalidated the trademark licensing agreements between Guangzhou Pharmaceutical Group and Jia Duo Bao's parent company [14]. - In 2023, a court ruled that Jia Duo Bao must pay 317 million yuan for trademark infringement, which Jia Duo Bao plans to appeal [14].

Core Viewpoint - The trademark dispute over "Wanglaoji" between JDB Group and Guangzhou Wanglaoji Health Industry Co., Ltd. has intensified, with both parties asserting their claims regarding overseas trademark ownership and registration [3][4]. Group 1: Trademark Dispute - JDB Group claims to have obtained the overseas trademark rights for "Wanglaoji" in the early 2000s and has registered the trademark in 60 countries [3]. - Guangzhou Wanglaoji Health Industry Co., Ltd. asserts that the current trademark owner is Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., and they have registered "Wanglaoji" in over 100 countries [4]. - The ongoing dispute has seen legal actions, including a recent court ruling that found JDB Group liable for infringement, resulting in a compensation order of 317 million yuan [4]. Group 2: Market Position and Strategy - As of June 2025, Wanglaoji holds a 46.33% market share in the plant beverage category, while JDB follows with 28.31% [4]. - Wanglaoji is expanding its international market presence with new product launches and partnerships, including the introduction of "WALOVI" branded cans in various international markets [5]. - The company reported a revenue of 6.499 billion yuan in the first half of 2025, reflecting an 8.38% year-on-year growth [5]. Group 3: Industry Growth - The global plant beverage industry is experiencing rapid growth, with a compound annual growth rate of nearly 10% projected from 2019 to 2024, particularly in emerging markets like Southeast Asia and the Middle East [6].

Group 1 - Zong Fuli has resigned from her positions as Chairman and General Manager of Wahaha Group, effective September 12, due to trademark compliance issues and plans to focus on her own brand "Wah Xiaozong" [3] - Core member Yan Xuefeng of Wahaha Group, previously under investigation, has returned to work after being cleared of allegations [3] - ByteDance founder Zhang Yiming made a public appearance for the first time in years, launching the Shanghai Xuhui Zhichun Innovation Center aimed at nurturing talent in computer science and AI [3] Group 2 - Qualcomm is under investigation by China's market regulator for allegedly failing to report its acquisition of Autotalks, potentially violating antitrust laws [5] - Xibei's founder responded to the logo change at a specific location, stating it is a small-scale trial and will not be implemented nationwide [5] Group 3 - ByteDance announced a new employee support policy providing up to 7.2 million yuan in transitional subsidies for employees laid off due to organizational adjustments [7] - DJI's recent price cuts on multiple products have led to controversy, with some stores in Shenzhen offering price difference refunds for purchases made during a specific period [7] - AI company Zhipu has denied rumors of layoffs before its IPO, stating it has nearly 50 job openings available [7] Group 4 - The ongoing trademark dispute between Jia Duo Bao and Wang Laoji has escalated, with both parties claiming ownership of the overseas Wang Laoji trademark [7] - Ding Tai Fung announced the closure of its WeChat store and has already shut down over ten physical locations due to brand operational adjustments [7] Group 5 - Former CBO of Zeekr, Guan Haitao, confirmed his departure from the company for personal reasons [10] - Pop Mart's Halloween series blind boxes sold out quickly, with one hidden variant seeing a price increase of over 13 times its original price [10] Group 6 - Zheng Qinwen has been named the first global brand ambassador for Bawang Tea [11] - TIME magazine's annual list of 300 best inventions includes products from companies like Huawei, BYD, and Apple [11] Group 7 - Great Wall Motors is adjusting its direct sales channels, with the Tank brand being phased out in favor of the Wey brand [16] - Meituan's community supermarket "Happy Monkey" is set to open its first northern store in Yanjiao, Hebei, on October 17 [16] Group 8 - Standard Chartered China has completed its first domestic RMB aircraft financing loan of 1 billion yuan for China Eastern Airlines [19] - Blue Sky Aviation has secured several million yuan in angel financing to develop its eVTOL products [20] Group 9 - Leapmotor has released teaser images for its luxury flagship SUV D19, set to debut on October 16 [21] - IDC reported that Lenovo holds a 25.5% market share in the global PC market, leading with 19.4 million units shipped [23]

加多宝和王老吉的海外"王老吉"商标之争继续发酵。 10月10日，加多宝集团发布关于海外"王老吉"商标所有权的声明称，加多宝集团自上世纪九十年代从王 老吉（正名王泽邦）后人手中取得祖传凉茶秘方及海外王老吉商标使用权，并于2000年初合法获得海外 王老吉商标所有权。 声明提及，为了让更多消费者认识中国的凉茶品类，加多宝集团积极开拓海外市场，在全球超过60个主 要国家和地区注册王老吉商标，巩固其市场上的地位和品牌形象。通过不断扩展营销渠道，深入市场， 加多宝集团拥有的海外王老吉品牌凉茶至今已远销全世界数十多个国家和地区。 二是关于加多宝集团蓄意误导"王老吉"境外商标的情况，王老吉称，加多宝集团所谓"侵权、假冒、不 正当竞争"的表述，是对商标法律定义的误读与误导，其通过海外离岸关联公司万捷有限公司在全球60 余个国家和地区进行恶意注册，干扰公司正常拓展海外业务。针对加多宝集团的上述恶意行径，王老吉 坚决采取维权行动。在中国澳门、中国台湾、澳大利亚、巴西、韩国、日本、德国、法国、新西兰等21 个国家/地区，以商标不使用撤销、商标无效宣告的程序对其恶意注册行为进行打击。现已有10个国家/ 地区的审理机关作出撤销其商标的决 ...

Core Viewpoint - The trademark dispute over "Wanglaoji" has intensified, with both JDB Group and Guangzhou Wanglaoji Health Industry Co., Ltd. claiming ownership of the overseas trademark rights [1] Group 1: JDB Group's Position - On October 10, JDB Group announced it holds the overseas trademark rights for Wanglaoji, claiming to have acquired the rights from Wanglaoji's descendants in the 1990s [1] - JDB Group asserts that it legally obtained the overseas trademark ownership in the 2000s and has registered the Wanglaoji trademark in 60 major countries and regions worldwide [1] - The company plans to take legal action to protect its rights against what it describes as false claims regarding the overseas Wanglaoji brand rights [1] Group 2: Guangzhou Wanglaoji Health Industry Co., Ltd.'s Position - On September 30, Guangzhou Wanglaoji Health Industry Co., Ltd. accused JDB Group of malicious trademark registration, asserting that the Wanglaoji trademark is owned by Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. [1] - The company claims to have registered the "Wanglaoji" and "WALOVI" series trademarks in over 100 countries and regions globally [1] - It alleges that JDB Group has interfered with its normal overseas business expansion through malicious registrations by offshore affiliates [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州白雲山醫藥集團股份有限公司 （「本公司」） 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00874 | 說明 | 香港聯交所上市 H 股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 219,900,000 RMB | | | 1 RMB | | 219,900,000 | | 2. 股 ...

Core Viewpoint - The ongoing trademark dispute between Wanglaoji and JDB (Jiangxi Daba) has intensified, with both companies claiming rights to the "Wanglaoji" brand in various international markets, leading to legal battles and public statements that reflect their opposing positions [1][2][4]. Trademark Dispute - JDB claims to hold valid "Wanglaoji" trademarks in 63 countries and regions, including North America, South America, Europe, Asia, Africa, and Oceania, and has successfully defended these trademarks in multiple lawsuits [2][4]. - Wanglaoji asserts that JDB's claims of "infringement, counterfeiting, and unfair competition" are misinterpretations of trademark law, stating that JDB's registrations are malicious and lack legal basis [2][5]. - The Guangdong High People's Court ruled in July 2023 that JDB companies were jointly infringing on Wanglaoji's trademark rights, ordering them to pay 317 million yuan in damages, which JDB plans to appeal [3]. International Legal Context - JDB has reported favorable rulings in Canada and the EU, confirming the legality of its trademark registrations and usage in those regions [4]. - Wanglaoji is actively challenging JDB's registrations in 21 countries, with 10 countries already ruling in favor of Wanglaoji, including regions where JDB claims valid registrations [5]. Market Dynamics - The competition between Wanglaoji and JDB has extended beyond legal battles to international markets, with both brands vying for dominance in the growing plant-based beverage sector [8]. - According to Frost & Sullivan, the global plant beverage industry is experiencing explosive growth, with a compound annual growth rate (CAGR) of nearly 10% from 2019 to 2024, particularly in emerging markets like Southeast Asia and the Middle East [8]. - Wanglaoji holds a 46.33% market share in the plant beverage category in China, while JDB follows with 28.31% [8]. International Expansion Efforts - Wanglaoji has accelerated its international expansion, forming partnerships for localized production and distribution in various countries, including Malaysia, Vietnam, and Cambodia [9]. - The company reported a significant increase in overseas market size, growing 6.5 times over the past decade, with an annual growth rate exceeding 25% [9]. - Wanglaoji's revenue for the first half of the year reached 6.499 billion yuan, with a net profit of 1.295 billion yuan, both showing double-digit growth [9].

Core Viewpoint - On September 30, Baiyunshan's stock increased by 0.24% with a trading volume of 219 million yuan, indicating active market participation and interest in the company [1] Financing Summary - On September 30, Baiyunshan had a financing buy-in amount of 22.36 million yuan and a financing repayment of 45.28 million yuan, resulting in a net financing outflow of 22.92 million yuan [1] - As of September 30, the total financing and securities lending balance for Baiyunshan was 1.015 billion yuan, with the financing balance at 1.013 billion yuan, accounting for 2.82% of the circulating market value, which is above the 90th percentile of the past year [1] - In terms of securities lending, Baiyunshan repaid 21,200 shares and sold 500 shares on September 30, with a selling amount of 12,800 yuan, while the securities lending balance was 1.99 million yuan, exceeding the 60th percentile of the past year [1] Company Overview - Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. was established on September 1, 1997, and listed on February 6, 2001, with its main business involving the research, development, manufacturing, and sales of traditional Chinese and Western medicines, chemical raw materials, and health products [2] - The revenue composition of Baiyunshan includes 69.32% from large commercial operations, 16.79% from health products, and 12.53% from traditional Chinese medicine, with specific contributions from various segments [2] - As of June 30, 2025, Baiyunshan reported a revenue of 41.835 billion yuan, a year-on-year increase of 1.93%, while the net profit attributable to shareholders was 2.516 billion yuan, a decrease of 1.31% year-on-year [2] Dividend and Shareholding Information - Baiyunshan has distributed a total of 10.906 billion yuan in dividends since its A-share listing, with 4.359 billion yuan distributed in the last three years [3] - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited, which increased its holdings by 9.36 million shares, and Huatai-PB CSI 300 ETF, which also saw an increase in holdings [3]

每经AI快讯，天眼查工商信息显示，近日，广药云山分子科技（广州）有限公司成立，法定代表人为孔箭，注册资本5亿元人民币，经营范围为医学研究和 试验发展，技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广，以自有资金从事投资活动，第二类医疗器械销售，食品互联网销售，食品销 售。股东信息显示，该公司由白云山（600332）全资持股。 | | | 皇公司 都在用的商业查询工具 | 查关系 查风险 省老板 | | | | --- | --- | --- | --- | --- | --- | | | | 国家中小企业发展子基金旗下机构 | 广药云山分子科技（广州）有限公司 | × 天眼一下 | | | 基本信息 17 | | 法律诉讼 | 经营风险 | 经营信息 | 公 | | 法定代表人 | | 孔箭 猛关联企业 4 FL | 登记状态 ② | 存续 | | | | | | 成立日期 | 2025-09-30 | | | 统一社会信用代码 2 | | 91440112MAEWX6L36M | 注册资本 2 | 50000万人民币 | | | 工商注册号 | | 440112005294751 | 纳税人识别号 ...

白云山为何要入股南京医药？除了通过受让股权成为南京医药第二大股东外，白云山还与南京医药签署 了战略投资协议，双方积极制定市场拓展与渠道共享方案，整合优化供应链资源和物流配送网络，建立 稳定、高效的供应链体系等，实现协同发展。 入股地处江苏的南京医药，白云山将加码布局华东市场。 受近年来政策及市场变化等多种因素影响，白云山的经营业绩也出现了小幅调整。入股南京医药，白云 山谋求突围。 战投南京医药（600713.SH），广药集团旗下的白云山（600332.SH）将间接成为南京医药的第二大股 东。 近期，白云山及南京医药均公告，2025年9月26日，白云山附属企业广州广药二期基金股权投资合伙企 业（有限合伙）（简称"广药二期基金"）与相关方签署协议，拟受让南京医药11.04%的股权，交易价款 约7.49亿元。 长江商报消息 ●长江商报记者 沈右荣 分析人士认为，无论是医药制造还是医药流通环节，市场竞争加剧，"野蛮生长"时代已经过去，通过股 权纽带，寻求协同发展或将是突围之道。 携7.49亿入股南京医药 通过受让股权，白云山成了南京医药间接第二大股东。 2025年9月28日，白云山发布公告，公司附属企业广药二期基金与 ...